Diffuse large B-cell lymphoma
Conditions
Interventions
Case series:D-R-GDP
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years old, ECOG score 0-2, expected survival time > 12 weeks; 2. In patients with diffuse large B-cell lymphoma confirmed by histopathology, CD20 was positive. 3. There was no contraindication of chemotherapy: hemoglobin >=9.0g / L, absolute neutrophil count >=1500L, platelet >=100000L, alt, AST <=2 times normal upper limit, serum total bilirubin <=1.5 times normal upper limit. Serum creatinine <=1.5 times the normal upper limit; 4. At least one measurable lesion; 5. There were no other serious diseases conflicting with this scheme, and the cardiopulmonary function was basically normal; 6. Women of childbearing age were negative in urine or blood pregnancy test within 7 days. Male and female patients should agree to use effective contraceptive measures during treatment and in the following year; 7. Be able to understand this study and sign an informed consent form before screening.
Exclusion criteria
Exclusion criteria: 1. Patients without initial treatment or recurrence; 2. Double hit lymphoma; 3. Patients who had been treated with past aberrant methylation inhibitors; 4. With central nervous system (meninges or brain parenchyma) involved; 5. Patients who plan to receive subsequent autologous stem cell transplantation; 6. Refusing to provide blood or tissue specimens; 7. More than one chemotherapy regimen has been received in the past. 8. Peripheral neuropathy >=2 grade; 9. There are drug allergies or metabolic disorders to the drugs in this program; 10. Those who refuse to use reliable contraceptive methods during pregnancy, lactation or appropriate age; 11. There are any uncontrollable medical diseases (including uncontrolled diabetes, severe heart, lung, liver, renal insufficiency); twelve Patients with severe infection or active bleeding; 13. There are contraindications of chemotherapy or targeted therapy; 14. He has suffered from other malignant tumors in the past; 15. Mental disorders / persons who are unable to obtain informed consent; 16. The researchers determined that they were not suitable for participating in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CR;PR;ORR;PFS;OS; | — |
Countries
China
Contacts
Public ContactLiling zhang
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed